QARZIBA dinutuximab beta 4.5 mg/mL concentrate for solution for infusion, 20 mg/4.5 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

qarziba dinutuximab beta 4.5 mg/ml concentrate for solution for infusion, 20 mg/4.5 ml vial

recordati rare diseases australia pty ltd - dinutuximab beta, quantity: 4.5 mg/ml - solution - excipient ingredients: polysorbate 20; hydrochloric acid; sucrose; water for injections; histidine - qarziba is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response.

SIGNIFOR LAR pasireotide 60 mg (as embonate) modified release powder for injection vial and 2 mL diluent in prefilled syringe composite pack Australia - English - Department of Health (Therapeutic Goods Administration)

signifor lar pasireotide 60 mg (as embonate) modified release powder for injection vial and 2 ml diluent in prefilled syringe composite pack

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 82.26 mg (equivalent: pasireotide, qty 60 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

SIGNIFOR LAR pasireotide 40 mg (as embonate) modified release powder for injection vial and 2 mL diluent in prefilled syringe composite pack Australia - English - Department of Health (Therapeutic Goods Administration)

signifor lar pasireotide 40 mg (as embonate) modified release powder for injection vial and 2 ml diluent in prefilled syringe composite pack

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 54.84 mg (equivalent: pasireotide, qty 40 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

SIGNIFOR LAR pasireotide 20 mg (as embonate) modified release powder for injection vial and 2 mL diluent in prefilled syringe composite pack Australia - English - Department of Health (Therapeutic Goods Administration)

signifor lar pasireotide 20 mg (as embonate) modified release powder for injection vial and 2 ml diluent in prefilled syringe composite pack

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 27.42 mg (equivalent: pasireotide, qty 20 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

SIGNIFOR pasireotide 900 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 900 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 1128.6 microgram (equivalent: pasireotide, qty 900 microgram) - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; tartaric acid - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

SIGNIFOR pasireotide 300 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 300 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 376.2 microgram (equivalent: pasireotide, qty microgram) - injection, solution - excipient ingredients: water for injections; mannitol; tartaric acid; sodium hydroxide - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

SIGNIFOR pasireotide 600 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 600 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 752.4 microgram (equivalent: pasireotide, qty 600 microgram) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; tartaric acid; mannitol - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

CYSTADANE betaine 1g/g oral powder bottle Australia - English - Department of Health (Therapeutic Goods Administration)

cystadane betaine 1g/g oral powder bottle

recordati rare diseases australia pty ltd - betaine, quantity: 1 g/g - powder, oral - excipient ingredients: - as an adjunct in the treatment of homocystinuria.

PEDEA ibuprofen 10 mg/2 mL solution for intravenous infusion 2 mL glass ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

pedea ibuprofen 10 mg/2 ml solution for intravenous infusion 2 ml glass ampoule

recordati rare diseases australia pty ltd - ibuprofen, quantity: 5 mg/ml - injection, solution - excipient ingredients: trometamol; sodium hydroxide; sodium chloride; hydrochloric acid; water for injections - pedea is indicated for the treatment of haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.

Cosmegen dactinomycin (actinomycin D) 0.5mg injection Australia - English - Department of Health (Therapeutic Goods Administration)

cosmegen dactinomycin (actinomycin d) 0.5mg injection

recordati rare diseases australia pty ltd - dactinomycin, quantity: 500 microgram - injection, powder for - excipient ingredients: mannitol - wilm's tumour; rhabdomyosarcoma; carcinoma of the testes and uterus. other neoplasms: actinomycin d given iv or by regional perfusion, either alone or with other antineoplastic compounds or with x-ray therapy in the palliative treatment of ewing's sarcoma and sarcoma botryoides; non-metastatic ewing's carcinoma. actinomyin d and radiation therapy; actinomycin d in various types of sarcoma, carcinoma and adenocarcinoma using isolation-perfusion technique. for full list of indications refer to approved pi document.